Via Business Insider NEW YORK, Oct. 8, 2020 /PRNewswire/ — INTRODUCTIONDepression is one of the most common chronic neurological conditions in modern society. It is estimated that over 250 million people, across all age groups, suffer from some form of depression, worldwide. Moreover, this condition along with other mental health disorders are estimated to be responsible for …
Global Psychedelic Therapeutics Market, 2020-2030 Read More »
Via Motley Fool What happened Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker’s shares promptly rose by an eye-catching 70.5% during their first day of trading on the Nasdaq stock exchange. Compass’ upward momentum, following this historic public debut, appears set to …
Via benzinga Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol CMPS. With the filing, Compass expects to raise about $100 million that will …
Via Bloomberg Compass Pathways Plc., a U.K. startup backed by tech billionaire Peter Thiel and lead investor Christian Angermayer, has filed to go public about four years after it was founded to explore the use of a psychedelic compound found in so-called magic mushrooms for treating depression. The London-based firm filed to raise $100 million, …
Magic Mushroom Drug-Backer Compass Pathways Files for U.S. IPO Read More »
